Abstract:Inverse protein folding generates valid amino acid sequences that can fold into a desired protein structure, with recent deep-learning advances showing significant potential and competitive performance. However, challenges remain in predicting highly uncertain regions, such as those with loops and disorders. To tackle such low-confidence residue prediction, we propose a \textbf{Ma}sk \textbf{p}rior-guided denoising \textbf{Diff}usion (\textbf{MapDiff}) framework that accurately captures both structural and residue interactions for inverse protein folding. MapDiff is a discrete diffusion probabilistic model that iteratively generates amino acid sequences with reduced noise, conditioned on a given protein backbone. To incorporate structural and residue interactions, we develop a graph-based denoising network with a mask prior pre-training strategy. Moreover, in the generative process, we combine the denoising diffusion implicit model with Monte-Carlo dropout to improve uncertainty estimation. Evaluation on four challenging sequence design benchmarks shows that MapDiff significantly outperforms state-of-the-art methods. Furthermore, the in-silico sequences generated by MapDiff closely resemble the physico-chemical and structural characteristics of native proteins across different protein families and architectures.
Abstract:We investigate the potential of patent data for improving the antibody humanness prediction using a multi-stage, multi-loss training process. Humanness serves as a proxy for the immunogenic response to antibody therapeutics, one of the major causes of attrition in drug discovery and a challenging obstacle for their use in clinical settings. We pose the initial learning stage as a weakly-supervised contrastive-learning problem, where each antibody sequence is associated with possibly multiple identifiers of function and the objective is to learn an encoder that groups them according to their patented properties. We then freeze a part of the contrastive encoder and continue training it on the patent data using the cross-entropy loss to predict the humanness score of a given antibody sequence. We illustrate the utility of the patent data and our approach by performing inference on three different immunogenicity datasets, unseen during training. Our empirical results demonstrate that the learned model consistently outperforms the alternative baselines and establishes new state-of-the-art on five out of six inference tasks, irrespective of the used metric.